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InﬂammationmayactivatestemcellsviaprostaglandinE2(PGE2)productionmediatedbycyclooxygenase-2 (COX-2)expression.
We performed an immunohistochemical analysis of the expression of stemness markers (Oct3/4 and CD44v6) and COX-2
in urinary bladder tissues obtained from cystitis and cancer patients with and without Schistosoma haematobium infections.
Immunoreactivity to Oct3/4 was signiﬁcantly higher in S. haematobium-associated cystitis and cancer tissues than in normal
tissues. CD44v6 expression was signiﬁcantly higher in bladder cancer without S. haematobium than in normal tissues. COX-2
was located in the cytoplasmic membrane, cytoplasm, and nucleus of the cancer cells. Interestingly, the nuclear localization of
COX-2, which was reported to function as a transcription factor, was signiﬁcantly associated with the upregulation of Oct3/4 and
CD44v6 in bladder cancer tissues with and without S. haematobium infection, respectively. COX-2 activation may be involved in
inﬂammation-mediated stem cell proliferation/diﬀerentiation in urinary bladder carcinogenesis.
1.Introduction
Chronic inﬂammation, in which large amounts of reactive
oxygen/nitrogen species (ROS/RNS) and cytokines are pro-
duced, is a well-recognized cause of cancer [1]. Epidemio-
logic and animal studies have indicated chronic inﬂamma-
tion including urinary tract infections to be involved in the
development of bladder cancer [2, 3]. Infections by parasites
such as Schistosoma haematobium (S. haematobium), which
act as inﬂammatory agents, are associated with urinary blad-
der cancer [4]. One mechanism of carcinogenesis involves
the eggs of parasites [5, 6]. The deposition of parasite eggs
in the host bladder results in irritation, eventual ﬁbrosis, and
chronic cystitis, leading to carcinogenesis [6]. In areas where
S.haematobiumisnot endemic,sporadic bladdercancermay
be caused by environment factors, such as smoking [7, 8],
and genetic polymorphisms in tumor suppressor [9–11],
drug metabolism [12], and anti-oxidant [13]g e n e s .
Recently,evidenceisaccumulatingtoshowthatstemcells
are involved in inﬂammation-related carcinogenesis. Ac-
cording to the cancer stem cell hypothesis, not all tumor cells
can participate in tumor evolution, and instead, this prop-
erty is limited to a subset of cells, termed “cancer stem cells”
[14, 15]. Several reports have suggested Oct3/4 to play roles
in tumor progression and regulation of the motility of blad-
der cancer cells [16, 17]. Bentivegna et al. reported the
existence of cancer stem cell-like populations in bladder can-
cer patients, using markers including Oct3/4 [18]. Our re-
cent report demonstrated that Oct3/4 was expressed not
only in bladder cancer but also in cystitis tissues in S. hae-
matobium-infected patients [19], suggesting a property of
stem cell. CD44 is a receptor for hyaluronic acid, and its var-
iant isoform 6 (CD44v6) is a molecular marker for bladder
cancer [20]. Several reports have showed that loss of CD44v6
expression in urinary bladder cancer is associated with tu-
mor dediﬀerentiation, abnormal DNA content, and a poor2 Mediators of Inﬂammation
Table 1: Pathological analysis of urinary bladder tumor tissues.
Risk factor Pathology diagnosis Tumor grade Case









Adenocarcinoma Moderately diﬀerentiated 1





Squamous cell carcinoma Moderately diﬀerentiated 1
Adenocarcinoma Moderately diﬀerentiated 1
Poorly diﬀerentiated 1
prognosis [20–22]. However, others reported that CD44v6
was associated with cell migration, tumor growth, and pro-
gression, and the expression of CD44v6 is correlated with the
proliferation of poorly diﬀerentiated urothelial cells [23–25].
These controversial results were reported in previous papers
on the relationship between CD44v6 expression and the
biologicalbehaviorofurothelialcells.Interestingly,recentre-
ports suggested that CD44v6-positive cells possessed a char-
acteristic phenotype of tumor-initiating cancer stem cell in
brain tumor [26]a n db l a d d e rc a n c e r[ 23, 25]. These reports
let us hypothesize that Oct3/4 and CD44v6 may be involved
in establishing a stem-like cell phenotype in bladder cancer.
Prostaglandin E2 (PGE2) has been reported to regulate
vertebrate hematopoietic stem cell homeostasis [27]. In-
ﬂammation may also activate normal or cancer stem cells
via PEG2 signaling [28]. It is accepted that cyclooxygenase-
2 (COX-2), the PGE2-generating enzyme, is important to
inﬂammation-relatedcarcinogenesis.Usingraturinaryblad-
der carcinogenesis induced by N-butyl-4-N-(4-hydroxybu-
tyl) nitrosamine (BBN) as a model, the increased expression
of the COX-2 protein was found in preneoplastic and neo-
plastic lesions of tumor tissues [29], and COX inhibitors ex-
hibited antitumor activity [30]. Expression of COX-2 had
been demonstrated in transitional cell [31] and squamous
cell [32] carcinomas of urinary bladder and S. haematobium-
associated urinary bladder cancer patients [33]. Therefore,
we have assumed that COX-2 plays important roles in not
onlytumorinitiation/promotionbutalsointheregulationof
stem cell proliferation and diﬀerentiation in inﬂammation-
related urinary bladder carcinogenesis.
To understand carcinogenic mechanisms in relation to
stem cell activation during inﬂammation, we examined the
expression of COX-2 and stemness markers (Oct3/4 and




2.1. Patients. Formalin-ﬁxed and paraﬃn-embedded biopsy
and surgical specimens were obtained from 33 cases of blad-
dercancerassociatedwithS.haematobiuminfections(9cases
of squamous cell carcinoma (SCC), 23 cases of transitional
cell carcinoma (TCC) and 1 case of adenocarcinoma) and
12 cases of cystitis induced by S. haematobium from the
Theodor Bilharz Research Institute in Egypt. We assessed
pathological grades of urinary bladder cancer according to
the World Health Organization Classiﬁcation [34, 35]a s
shown in Table 1. S. haematobium egg antigens in sera were
detected by Sandwich ELISA [36]. This study was performed
in accordance with the Ethical Guidelines for Epidemiologi-
cal Research enacted by the Japanese government. We re-
moved identifying information from all samples before anal-
ysis.
Urinary bladder cancer tissus caused by other risk factors
(no S. haematobium infection, 1 case of SCC, 2 cases of
adenocarcinoma, and 37 cases of TCC) and normal tissues
adjacent to tumors (31 cases) were obtained from a commer-
cial urinary bladder tissue array (Cat.No.BL801, Biomax.us,
USA). Normal tissues with cystitis were excluded.
2.2.ImmunoﬂuorescenceAnalysis. ImmunoreactivitytoCOX
-2, Oct3/4, and CD44v6 in bladder tissues was as-sessed by
single or double immunoﬂuorescence labeling, as described
previously [37]. Brieﬂy, deparaﬃnized and dehydrated sec-









Figure 1: Localization of COX-2 in urinary bladder cancer. COX-2 (red) was stained by an immunoﬂuorescence method in urinary bladder
tissues including normal (SH−) and cancer (SH+) tissues. (a) COX-2 was very weakly expressed in normal tissues. Scale bar is equal to
20μm. (b) COX-2 staining was observed only in the cytoplasm of cancer cells. (c) COX-2 was strongly expressed in both the cytoplasm and
nucleus of cancer cells. Arrows indicate nuclear positive staining. (d) COX-2 was strongly expressed in the nucleus of cancer cells. SH: S.
haematobium infection.
and incubated with a PBS-diluted antibody (mouse mon-
oclonal anti-Oct3/4 (1:50, Santa Cruz Biotech-nology),
mouse monoclonal anti-CD44v6 (1:100, Abcam), or rabbit
polyclonal anti-COX-2 (1:200, Calbiochem)) overnight at
room temperature. The sections were incubated for 3 hours
with Alexa 594-labeled goat antibody against rabbit IgG
or Alexa 488-labeled goat antibody against mouse IgG
(1:400) (Molecular Probes, Eugene, Oregon, USA). The
stained sections were examined under a confocal laser
scanning microscope (FV-1000, Olympus, Tokyo, Japan) or
ﬂuorescence microscopy (BX53, Olympus, Tokyo, Japan).
2.3. Immunohistochemical Grading. We deﬁned immunohis-
tochemical grading (IHC grading) based on intensity and
frequency derived from the staining results. The staining
intensity was scored as negative (0), weak (+1), moderate
(+2), or strong (+3). The frequency of positive cells in a
section was scored as negative (0), less than 25% (+1), 25–
50% (+2), 51–75% (+3), or more than 75% (+4). IHC
grading was assigned by multiplying the intensity score by
the frequency score, as follows: −, absent expression (0); +,
weakexpression (1–4),++, moderateexpression (5–8); +++,
high expression (9–12).
2.4. Statistical Analysis. The signiﬁcance of diﬀerences was
determinedbyChi-squaretest.P<0.05wasconsideredtobe
statisticallysigniﬁcant.Thestatisticalanalysiswasperformed
using SPSS19 for Windows.
3. Results
3.1. Expression of COX-2 in Urinary Bladder Tissues. COX-2
was detected in the plasma membrane, cytoplasm, and nu-
cleusinhyperplasiaandprecancerousandcancercells.COX-
2 was expressed very weakly in normal urinary bladder tis-
sues (Figure 1(a)). S. haematobium-associated urinary blad-
der cancer tissue had strong expression of COX-2 in only cy-
toplasm of cancer cells (Figure 1(b)), which was described as
Table 2: Expression of COX-2, Oct3/4 and CD44v6 in urinary
bladder samples.
(a) COX-2
$COX-2 staining − + ∗P value
Normal (SH−)2 6 5
Cancer (SH−)4 3 6 <0.001a
Cystitis (SH+) 5 7 0.006a
Cancer (SH+) 13 20 <0.001a
(b) Oct3/4
#IHC grading − + ++ +++ P value
Normal (SH−)1 9 1 1 0 1
Cancer (SH−) 30 10 0 0 0.299a
Cystitis (SH+) 3 7 2 0 0.031a
Cancer (SH+) 8 17 2 6 0.010a <0.001b
(c) CD44v6
IHC grading − + ++ +++ P value
Normal (SH−)1 4 1 4 2 1
Cancer (SH−) 3 11 15 11 <0.001a
Cystitis (SH+) 6 3 2 1 0.496a
Cancer (SH+) 19 9 4 1 0.484a <0.001b
$COX-2 staining results were assigned as (−)n e g a t i v ea n d( + )p o s i t i v e
staining.
#IHC grade was assigned to each specimen according to the degree of
staining as described in Materials and Methods.
SH: S. haematobium infection.
∗P values were calculated by Chi-square test. aVersus normal (SH−).
bVersus cancer (SH−).
a cytoplasmic staining. Figure 1(c) shows the COX-2 stain-
inginboththecytoplasmandnucleus,whileFigure 1(d)rep-
resents strong expression of COX-2 in nucleus of the
cancer cells. We assigned the patterns shown in Figures
1(c) and 1(d), as positive for nuclear localization of COX-
2. Table 2 summarizes the results of COX-2 expression in
urinarybladdertissues.COX-2stainingwasobservedin16%
(5/31) of normal bladder samples. The expression of COX-24 Mediators of Inﬂammation







































Figure 2: Colocalization of Oct3/4 and COX-2 in urinary bladder samples. The distribution of Oct3/4 (green) and COX-2 (red) was
determined by double immunoﬂuorescence in urinary bladder tissues from normal, S. haematobium-associated cystitis and cancer subjects.
Original magniﬁcation is 200x. Enlarged: enlargement of dotted areas. SH: S. haematobium infection.
was signiﬁcantly increased in 90% (36/40) of bladder cancer
patients without S. haematobium infections (P<0.001
compared to normal tissues). It was also detected in 61%
(20/33) of bladder cancer patients and 58% (7/12) of cystitis
patients infected with S. haematobium (P<0.001 and P =
0.006, resp., compared to normal tissues).
3.2. Expression of Oct3/4 and COX-2 in Urinary Bladder
Tissues. The expression of Oct3/4 and COX-2 in urinary
bladder tissues is shown in Figure 2. Oct3/4 was weakly
stained in normal epithelium cells. The mucosal layer and
precancerous area in cystitis patients with S. haematobium
infections exhibited strong Oct3/4 signals in nuclei of the
mucosa, as well as in urothelial epithelium with glandular
metaplasia. The stem cell marker was also strongly expressed
in the nucleus of bladder cancer cells of patients infected
with S. haematobium. Conversely, cancer tissues without
S. haematobium infections showed weak immunoreactivity
to Oct3/4 (data not shown). As summarized in Table 2,
immunoreactivity to Oct3/4 was signiﬁcantly higher in
S. haematobium-associated cystitis and cancer tissues than
normal tissues (P = 0.031 and P = 0.010, resp.). The
expressionofOct3/4wassigniﬁcantlyhigherincancertissues
with the infection than without (P<0.001). Interestingly,
the tumor tissues of patients infected with S. haematobium
exhibited strong colocalization of Oct3/4 and COX-2 in
cancer cell nuclei.
3.3. Expression of CD44v6 and COX-2 in Urinary Bladder
Tissues. Figure 3 shows the localization of CD44v6 and
COX-2 in bladder tissues without S.haematobium infection.
CD44v6 localized primarily to the cell membrane, and also
to the nuclear membrane. CD44v6 expression was observed
at the basal layer of mucosal cells in normal bladder tissues.
CD44v6 was also stained in the transitional (mucosal) and
precancerous cells of tissues in infected cystitis tissues.
Interestingly, most cells from hyperplasia areas and cancers
without S. haematobium (cancer (SH−)) expressed CD44v6,
whereas, the cells from cancers with the parasite (cancer
(SH+))expressed less CD44v6. Asshown in Table 2, CD44v6
expressionwassigniﬁcantlyhigherinbladdercancerwithout
S. haematobium than in normal tissues without the infection
(P<0.001). No signiﬁcant increase was observed in S.
haematobium-associated cystitis (P = 0.496) or urinary
bladder cancer (P = 0.484) compared with normal tissues.
Moreover, the immunoreactivity of the stemness marker was
signiﬁcantly higher in urinary bladder cancer tissues without
S. haematobium infection than in the S. haematobium-
associated cancer tissues (P<0.001).
3.4. Nuclear Localization of COX-2 in Urinary Bladder
Cancer. Table 3 shows COX-2 expression in relation to the
expression of stemness markers in urinary bladder cancer.
The expression of Oct3/4 in S. haematobium-associated
urinary bladder cancer tissues tended to increase in theMediators of Inﬂammation 5










































Figure 3: Localization of CD44v6 and COX-2 in urinary bladder samples. The distribution of CD44v6 (green) and COX-2 (red) was
determined by double immunoﬂuorescence in normal tissue, hyperplasic tissue nearby tumor, and cancer of urinary bladder tissue. These
subjects had other risk factors without S. haematobium infections. Original magniﬁcation is 200x. Enlarged: enlargement of dotted areas.
SH: S. haematobium infection.
patients with COX-2 expression (P = 0.060). Interestingly,
a signiﬁcant association was observed between the up-
regulation of Oct3/4 and nuclear localization of COX-2
in bladder cancer tissues from patients infected with S.
haematobium (P = 0.001). By contrast, the upregulation
of CD44v6 was signiﬁcantly associated with the expression
of COX-2 in urinary bladder cancer patients without the
infection (P = 0.002). The nuclear localization of COX-2
was more strongly associated with CD44v6 expression (P<
0.001).
4. Discussion
Inﬂammation is a well-recognized cause of cancer [38].
However, cancer itself can cause inﬂammation through
the production of proinﬂammatory factors such as NF-κB,
matrix metalloproteases (MMPs), inﬂammatory cytokines,
and chemokines [38, 39]. Inﬂammation-associated tissue
injury may activate stem cells [40, 41]. PGE2 has been
reported to function as a potent regulator of hematopoietic
stem cell diﬀerentiation, homing, survival, and proliferation
[27, 42]. In mouse embryonic stem cells, PGE2 also plays
a role in the induction of proliferation and suppression
of apoptosis [43, 44]. Moreover, PGE2 is found to induce
human mesenchymal stem cell migration and proliferation
mediated by interaction of proﬁlin-1 and F-actin via a beta-
arrestin-1/JNK signaling pathway [45]. Rudnick and co-
workers demonstrated that ﬁbroblasts secreting abundant
amounts of PGE2 were capable of enhancing tumor growth
in vivo and could increase the number of cancer stem-
like cells [46]. These results suggest that PGE2 plays a
crucial role in the regulation of several types of stem
cells. Many cancers including bladder cancer exhibit high
PGE2 levels due to upregulated expression of COX-2, a key
enzyme in PGE2 biosynthesis [31–33]. It is accepted that
COX-2 is important to inﬂammation-related carcinogenesis.
Therefore, inﬂammation may also activate normal or cancer
stem cells via PEG2 signaling [28]. The COX-2 enzyme
is generally expressed in the cytoplasm. However, studies
have indicated that its accumulation in the nucleus was
indicative of a functional role as a transcription factor in
regulating gene expression [47, 48]. Here, we found the
nuclear localization of COX-2 to be signiﬁcantly correlated
with expression of the stemness markers Oct3/4 and CD44v6
in S. haematobium-associated urinary bladder cancer and
cancer tissues without infection, respectively. These results
suggest that the activation of COX-2 in urinary bladder
carcinogenesis not only generates PGE2 but also may be
involved in the regulation of Oct3/4 and CD44v6 expression.
Oct3/4, a member of the family of POU-domain
transcription factors, is generally expressed in pluripotent6 Mediators of Inﬂammation
Table 3: Expression of Oct3/4 and CD44v6 in urinary bladder cancer patients positive and negative for COX-2 expression.
Risk factor Stemness marker #IHC grading
COX-2 expression Nuclear localization of COX-2
Negative case Positive case Negative case Positive case
S. haematobium infection (SH+)
Oct3/4
− 5380
+8 9 1 0 7
+ +0202
+++ 0 6 0 6
∗P-value P = 0.060 P = 0.001
CD44v6
− 91 0 1 09
+ 2754
+ +1322
+++ 1 0 1 0
P-value P = 0.320 P = 0.826
No S. haematobium infection (SH−)
Oct3/4
− 32 742 6
+ 1928
+ +0000
+++ 0 0 0 0




+ + 01 501 5
+ + +01 101 1
P-value P = 0.002 P<0.001
#IHC grade was assigned to each specimen according to the degree of staining as described in Materials and Methods.
SH: S. haematobium infection.
∗P values were calculated by Chi-square test.
embryonic stem and germ cells [49, 50]. The embryonic
stem cell marker has been reported to be involved in the
reprogramming of mature cells into germline-component-
induced pluripotent stem cells [51–53]. Recently, it is
suggested that Oct3/4 is also a cancer stem cell marker in
various types of tumors including urinary bladder cancer
[17]. Expression of Oct3/4 has been reported necessary
for maintaining the self-renewing, cancer stem-like, and
chemoradioresistant properties of tumorigenic stem-like cell
populations [54, 55]. In addition, Oct3/4 has been reported
to play roles in tumor progression and regulation of the
motility of bladder cancer cells [16, 17]. The present study
indicated that the expression of Oct3/4 was signiﬁcantly
increased in S. haematobium-associated cystitis and cancer
tissues compared with normal tissues. Therefore, Oct3/4
could be a useful stemness marker for parasite-related car-
cinogenesis in relation to the diﬀerentiation/reprogramming
of stem-like cells.
CD44 has been identiﬁed as a cell surface marker
associated with cancer stem cells in several types of tumors
including urinary bladder cancer [20]. Numerous isoforms
of CD44 are generated through alternative mRNA splicing
[56]. Variant isoforms (CD44v) with insertions in the
membrane-proximal extracellular region are abundant in
epithelial-type carcinomas and were found to be associated
with the progression of gastrointestinal malignancies [57].
Both CD44- and CD44v-positive stem cell-like phenotypes
have been reported to have high-capacity antioxidant sys-
tems rich in glutathione that result in growth arrest, cell
diﬀerentiation, and senescence and thereby promote the
proliferation of cancer cells [58, 59]. Moreover, expression
of CD44v6 is correlated with proliferation of poorly dif-
ferentiated urothelial cells and the characteristic phenotype
of tumor-initiating bladder cancer stem cells [23, 25]. In
this study, we also showed that CD44v6 was expressed in
the mucosa basal layer of normal and hyperplasia tissues,
and the expression was signiﬁcantly increased in bladder
cancer tissues compared to normal without the parasite.
Therefore, CD44v6 may have a relationship with sporadic
bladder cancer in the absence of the infection.
The present studydemonstrates thatdiﬀerentrisk factors
induce diﬀerent levels of expression of stemness markers
in urinary bladder carcinoma. S. haematobium-induced
urinary bladder cancer correlates with the expression of
Oct3/4, while the cancer without the infection correlates
with the expression of CD44v6. The expression of both
stemness markers was signiﬁcantly correlated with the
nuclear localization of COX-2, suggesting that inﬂamma-
tion might mediate stem cell proliferation and diﬀerentia-
tion/reprogramming in urinary bladder cancer.Mediators of Inﬂammation 7
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